FEDERAL COURT OF AUSTRALIA
Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5) [2013] FCA 1114
Citation: Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5) [2013] FCA 1114 Parties: BRISTOL-MYERS SQUIBB COMPANY and OTSUKA PHARMACEUTICAL CO., LTD v APOTEX PTY LTD (ACN 096 916 148) File number: NSD 1116 of 2009 Judge: YATES J Date of judgment: 30 October 2013 Catchwords: PATENTS – standard patent for improved form of anhydrous aripiprazole crystals having low hygroscopicity (Crystals B) – whether hygroscopicity is inherent property of given crystalline form of aripiprazole – whether disclosure of particular crystalline form of aripiprazole discloses its physicochemical properties including its hygroscopicity
PATENTS – validity – novelty – inevitable result – whether person skilled in the art carrying out directions in prior art patent specification before priority date would inevitably have obtained anhydrous aripiprazole crystals having the characteristic low hygroscopicity of Crystals B – whether directions in prior art patent specification disclose the invention as claimed
PATENTS – validity – novelty – whether disclosure of crystalline form of Crystals B in prior art publications discloses the invention as claimed – whether prior art publications should be treated as single source of information
PATENTS – validity – false suggestion or misrepresentation – statements in complete specification and correspondence in course of prosecuting application for patent
PATENTS – validity – inventive step – problem‑solution approach – whether person skilled in the art would be directly led as a matter of course to take steps that would lead to the invention as claimed
PATENTS – validity – manner of manufacture – whether working interrelationship between drug comprising Crystals B and commercial package carrying instructions for drug to be used to treat schizophrenia or its symptoms
PATENTS – validity – clarity – whether requirement that compound exhibits a particular endothermic peak is unclear for failure to specify whether one or more other endothermic peaks may also be present on analysis – whether requirement of mean particle size unclear for failure of claim to expressly stipulate a particular method of measuring mean particle size or range of particle sizes in a given sample
PATENTS – validity – fair basis – whether real and reasonably clear disclosure of Crystals B having certain particle size as part of invention
PATENTS – infringement – threatened infringement –contributory infringement – authorisation
PATENTS – standing to sue for infringement – whether first applicant is exclusive licensee of patent – right to manufacture aripiprazole under patent not conferred on licensee – consideration of meaning of “exclusive licensee”
Legislation: Copyright Act 1968 (Cth) s 101(1A)
National Health Act 1953 (Cth)
Patents Act 1949 (UK) s 101
Patents Act 1952 (Cth) ss 6, 96
Patents Act 1990 (Cth) ss 7, 13, 14, 18, 40, 117, 120(1), 138(3)Cases cited: Aktiebolaget Hässle and Another v Alphapharm Pty Limited (2002) 212 CLR 411
Alphapharm Pty Ltd (ACN 002 359 739) v H Lundbeck A/S and Another (2008) 76 IPR 618
Apotex Pty Ltd (ACN 096 916 148) v Sanofi‑Aventis and Others
Keep reading for free
Create a free CaseChat account to read Bristol-Myers Squibb Co v Apotex Pty Ltd (No 5) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] FCA 1114
- Decision Date
CaseChat Overview and Summary
The primary legal issue before the court was the interpretation of the licensing agreement between BMS and Apotex, specifically whether the agreement conferred exclusive rights or merely sole rights on BMS. The court also needed to assess the relevance and admissibility of certain pieces of evidence presented by both parties, including affidavits and recorded conversations. Additionally, the court had to consider the appropriateness of injunctive relief and declaratory relief in relation to the alleged infringement.
The court ruled that, while it was not necessary to definitively decide whether the agreement conferred exclusive or sole rights on BMS, it was inclined to interpret the agreement as granting exclusive rights. The court found that the language of the agreement did not indicate an intention to limit the rights to sole rights only. Regarding the evidence, the court admitted certain parts of the affidavits and recorded conversations, subject to relevance, and decided that they should be admitted unconditionally. The court indicated its provisional view that injunctive relief was appropriate, but declaratory relief regarding infringement might not be necessary. The court also noted the need for further submissions on specific aspects of the relief sought by BMS, particularly regarding the withdrawal of Apotex's application for pharmaceutical benefits scheme listing.
The court ordered the parties to prepare draft orders reflecting the reasons provided and indicated that further written submissions should be submitted if the parties could not agree on the orders. The court also allowed the parties' legal representatives a short period to review the reasons for any potential confidentiality claims before publication.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi